# To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

> **NCT00141479** · PHASE2 · COMPLETED · sponsor: **Solvay Pharmaceuticals**

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Bifeprunox

## Key facts

- **NCT ID:** NCT00141479
- **Lead sponsor:** Solvay Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** — (—)
- **Last updated:** 2015-01-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141479, "To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00141479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*